AIDS Myelopathy: Proof of concept for the therapeutical concept is reached
GENOPIA Biomedical GmbH announced today that a descriptive analysis of the data deriving from its clinical trial Phase II with patients suffering from AIDS Myelopathy resulted in a proof of concept for GENOPIA's strategy to treat these neurological dysfunctions. "Our compound is safe and well-tolerated in high doses without any evidence of toxicity." said Dr. Markus Weissbach, CMO of GENOPIA, "the efficacy results confirm our therapeutic concept and are an encouraging basis to perform a confirmatory follow up study. Lessons learned from the results of this study are a sufficiently long treatment period and a clearly defined patient population which should be considered when the effect of the compound is further evaluated. We are convinced that the upcoming phase III study will enable us to launch the first and only drug to treat AIDS Myelopathy in near future."
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.